Acral CD8+ TCLPD is rare, representing less than 1% of all CTCLs, and has a significantly less aggressive course than other CTCL subtypes (with the median 5-year-survival ranging between 75 and 100%), and therefore typically requires less intensive therapies [29]. The gene discussed is CD8A; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.